Guidelines of care for the management of primary cutaneous melanoma

Journal of the American Academy of Dermatology, Год журнала: 2018, Номер 80(1), С. 208 - 250

Опубликована: Ноя. 1, 2018

Язык: Английский

---

Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort

Journal of the American Academy of Dermatology, Год журнала: 2016, Номер 74(3), С. 455 - 461.e1

Опубликована: Янв. 12, 2016

Язык: Английский

---

Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond

Endocrine Reviews, Год журнала: 2019, Номер 40(6), С. 1573 - 1604

Опубликована: Июль 19, 2019

Abstract The treatment of advanced thyroid cancer has undergone rapid evolution in the last decade, with multiple kinase inhibitor drug approvals for each subtype and a number other commercially available drugs that have been studied this indication. Although most US Food Drug Administration (FDA)–approved are antiangiogenic multikinase inhibitors—vandetanib, cabozantinib, sorafenib, lenvatinib—there two FDA indications mutation specific—dabrafenib/trametinib BRAF-mutated anaplastic larotrectinib NTRK-fusion cancer. Furthermore, mutation-specific drugs, immunotherapies, novel strategies under investigation. Understanding molecular basis cancer, interest how these can be administered safely appropriate clinical scenario topics review.

Язык: Английский

---

Cutaneous adverse effects of the immune checkpoint inhibitors

Current Problems in Cancer, Год журнала: 2016, Номер 41(2), С. 125 - 128

Опубликована: Дек. 14, 2016

Язык: Английский

---

Vitiligo Pathogenesis and Emerging Treatments

Dermatologic Clinics, Год журнала: 2017, Номер 35(2), С. 257 - 265

Опубликована: Март 17, 2017

Язык: Английский

---

Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors

Supportive Care in Cancer, Год журнала: 2017, Номер 25(5), С. 1713 - 1739

Опубликована: Фев. 22, 2017

Язык: Английский

---

Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies

Cancer Management and Research, Год журнала: 2018, Номер Volume 10, С. 1259 - 1273

Опубликована: Май 1, 2018

Abstract: With the increasing use of targeted anticancer drugs and immunotherapies, there have been a substantial number reports concerning life-threatening severe cutaneous adverse reactions (SCARs), including Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia systemic symptoms, drug-induced hypersensitivity syndrome, acute generalized exanthematous pustulosis. Although potential risks characteristics for agent- immunotherapy-induced SCAR were not well understood, these serious usually result in morbidity sequela. As treatment guideline this devastating condition is still unavailable, prompt withdrawal causative believed to be priority patient management. In review, we outline distinct types SCARs caused by therapies immunotherapies. Also, discuss clinical course, latency, concomitant medication, tolerability rechallenge or alternatives, tumor response, mortality associated conditions. Imatinib, vemurafenib, rituximab top three offending medications that most commonly SJS/TEN, while EGFR inhibitors group frequently induced SJS/TEN. For symptoms/drug-induced pustulosis, imatinib was also common drug. Additionally, delineated 10 cases related innovative PD1 CTLA4 inhibitors. There wide range latency periods: 5.5–91 days (median). Only eight 16 reported patients showed responses. Targeted immunotherapies can lead lethal (14 deceased identified as suffering from SJS/TEN). The rate TEN high: up 52.4%. information compiled herein will serve solid foundation formulate ideas early recognition discontinue better Keywords: rash, eosinophilia, necrolysis, therapy, immunotherapy

Язык: Английский

---

Transient Receptor Potential Vanilloid 4 Ion Channel Functions as a Pruriceptor in Epidermal Keratinocytes to Evoke Histaminergic Itch

Journal of Biological Chemistry, Год журнала: 2016, Номер 291(19), С. 10252 - 10262

Опубликована: Март 10, 2016

TRPV4 ion channels function in epidermal keratinocytes and innervating sensory neurons; however, the contribution of channel either cell to neurosensory remains be elucidated. We recently reported as a critical component keratinocyte machinery that responds ultraviolet B (UVB) functions critically convert into pain-generator after excess UVB exposure. One key mechanism was increased expression secretion endothelin-1, which is also known pruritogen. Here we address question whether skin itch, particular form "forefront" signaling non-neural cells. Our results support this novel concept based on attenuated scratching behavior response histaminergic (histamine, compound 48/80, endothelin-1), not non-histaminergic (chloroquine) pruritogens Trpv4 keratinocyte-specific inducible knock-out mice. demonstrate rely for calcium influx pruritogens. activation evokes phosphorylation mitogen-activated protein kinase, ERK, This finding relevant because observed robust anti-pruritic effects with topical applications selective inhibitors MEK, kinase upstream suggesting via leads ERK-phosphorylation, turn rapidly converts an organismal itch-generator cell. In found behavior, evoked by direct intradermal TRPV4, dependent keratinocytes. Thus, pruriceptor-TRP basic translational-medical relevance.

Язык: Английский

---

A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors

Journal of Medical Toxicology, Год журнала: 2021, Номер 17(4), С. 411 - 424

Опубликована: Апрель 7, 2021

Язык: Английский

---

Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆

Annals of Oncology, Год журнала: 2020, Номер 32(2), С. 157 - 170

Опубликована: Ноя. 25, 2020

Язык: Английский

---